Greenwich Lifesciences Inc

GLSI remains entrenched in a Stage 4 decline following a decisive Support Failure. Price is extended into extreme oversold conditions but has only staged a bounce up to yet-unretested overhead EMAs. The medium-term bias is bearish, and preferred execution is deferred sell-side engagement on rallies into the declining 9/21 EMAs and 50 DMA rather than chasing current weakness.

• ↑MACD flipped positive on Aug 3, leading to gains 90% of past cases.
• ↑High momentum factors support continued price strength.
• ↓Anticipated -$0.33 EPS in Aug 2026 points to shrinking earnings.